Technical Analysis for FTSV - Forty Seven, Inc.

Grade Last Price % Change Price Change
grade F 15.48 0.39% 0.06
FTSV closed up 0.39 percent on Friday, February 15, 2019, on 81 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Feb 19

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Up
See historical FTSV trend table...

Date Alert Name Type % Chg
Feb 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Feb 15 Pocket Pivot Bullish Swing Setup 0.00%
Feb 15 Doji - Bearish? Reversal 0.00%
Feb 15 Weak + Overbought Other 0.00%
Feb 15 Outside Day Range Expansion 0.00%
Feb 15 Weak, Overbought and Reversal Signs Reversal 0.00%
Feb 15 Overbought Stochastic Strength 0.00%
Feb 15 Up 3 Days in a Row Strength 0.00%
Feb 15 Up 4 Days in a Row Strength 0.00%
Feb 15 Up 5 Days in a Row Strength 0.00%

Older signals for FTSV ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.
Medicine Cancer Medical Specialties Immunology Cancers Monoclonal Antibodies Cancer Immunotherapy Ovarian Cancer Acute Myeloid Leukemia Lymphoma Cancer Research Humanized Antibody NHL CD47
Is FTSV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.83
52 Week Low 12.02
Average Volume 173,708
200-Day Moving Average 0.0
50-Day Moving Average 16.2316
20-Day Moving Average 14.645
10-Day Moving Average 14.962
Average True Range 0.9439
ADX 9.56
+DI 19.1595
-DI 16.0104
Chandelier Exit (Long, 3 ATRs ) 13.4583
Chandelier Exit (Short, 3 ATRs ) 15.8317
Upper Bollinger Band 15.8073
Lower Bollinger Band 13.4827
Percent B (%b) 0.86
BandWidth 15.872994
MACD Line -0.1246
MACD Signal Line -0.2896
MACD Histogram 0.1651
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.87
Resistance 3 (R3) 16.79 16.26 16.64
Resistance 2 (R2) 16.26 15.90 16.29 16.56
Resistance 1 (R1) 15.87 15.69 15.60 15.94 16.48
Pivot Point 15.33 15.33 15.20 15.37 15.33
Support 1 (S1) 14.94 14.98 14.68 15.02 14.48
Support 2 (S2) 14.41 14.76 14.44 14.40
Support 3 (S3) 14.02 14.41 14.32
Support 4 (S4) 14.09